K-numberK242071
Device nameXpert Xpress CoV-2/Flu/RSV plus
ApplicantCepheid
Product codeQOF
Device classClass II
Decision dateJan 10, 2025
DecisionSubstantially Equivalent
Regulation866.3981
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Xpert Xpress CoV-2/Flu/RSV plus is an automated multiplexed real-time RT-PCR test that simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) RNA in nasopharyngeal and anterior nasal swab specimens from patients with respiratory infection symptoms. The test is performed on the GeneXpert Xpress System and aids in diagnosis when used with clinical and epidemiological information.

Technological characteristics

The subject device uses the same real-time reverse transcription polymerase chain reaction (RT-qPCR) technology as the predicate device, with identical assay targets (SARS-CoV-2, Flu A, Flu B, RSV), specimen types (NPS and NS in UTM/VTM/eNAT), and automated workflow. The key difference is the instrument platform: the subject device runs on the GeneXpert Xpress System, while the predicate ran on GeneXpert Dx and Infinity Systems. Both employ single-use self-contained cartridges with Sample Processing Control and Probe Check Control.

Test standards cited

The document cites Clinical and Laboratory Standards Institute (CLSI) document EP17-A2 for limit of detection studies. Standard performance evaluation metrics include Positive Percent Agreement (PPA), Negative Percent Agreement (NPA), and confidence intervals. In silico analysis was conducted against GISAID gene database sequences.

Substantial equivalence argument

Substantial equivalence is established because the subject device uses identical regulatory classification (21 CFR 866.3981, Class II), product code (QOF), assay technology (RT-qPCR), intended use (differential detection of four respiratory viruses), and assay design (same targets, controls, specimen types, and result interpretation) as the predicate. Analytical performance studies demonstrate equivalent sensitivity and specificity across diverse viral strains and specimen matrices. Clinical performance on 4,310+ prospective specimens shows PPA/NPA ≥96.6% across all targets. The only material change—the instrument platform—does not alter the test's fundamental analytical or clinical performance characteristics.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →